Study of Axicabtagene Ciloleucel Given With Steroids In Participants With Relapsed Or Refractory Large B-Cell Lymphoma
Public ClinicalTrials.gov record NCT05459571. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2 Open-Label, Multicenter Study Evaluating The Safety And Efficacy of Axicabtagene Ciloleucel Concomitant With Prophylactic Steroids In Subjects With Relapsed Or Refractory Large B-Cell Lymphoma In The Outpatient Setting
Study identification
- NCT ID
- NCT05459571
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Kite, A Gilead Company
- Industry
- Enrollment
- 35 participants
Conditions and interventions
Conditions
Interventions
- Axicabtagene Ciloleucel Biological
- Cyclophosphamide Drug
- Dexamethasone Drug
- Fludarabine Drug
Biological · Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 8, 2022
- Primary completion
- Nov 23, 2025
- Completion
- Nov 23, 2025
- Last update posted
- Feb 1, 2026
2022 – 2025
United States locations
- U.S. sites
- 16
- U.S. states
- 11
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| City of Hope (City of Hope National Medical Center, City of Hope Medical Center) | Duarte | California | 91010 | — |
| UCLA | Los Angeles | California | 90025 | — |
| Colorado Blood Cancer Institute | Denver | Colorado | 80218 | — |
| University of Maryland Greenebaum Comprehensive Cancer Center | Baltimore | Maryland | 21201 | — |
| Barbara Ann Karmanos Cancer Institute | Detroit | Michigan | 48201 | — |
| John Theurer Cancer Center at Hackensack University Medical Center | Hackensack | New Jersey | 07601 | — |
| Oncology Hematology Care Clinical Trials, LLC | Cincinnati | Ohio | 45242 | — |
| Prisma Health - Upstate | Greenville | South Carolina | 29615 | — |
| Tennessee Oncology, PLLC | Nashville | Tennessee | 37203 | — |
| Henry-Joyce Cancer Clinic | Nashville | Tennessee | 37232 | — |
| Methodist Healthcare System of San Antonio | San Antonio | Texas | 78229 | — |
| Intermountain Healthcare | Murray | Utah | 84107 | — |
| Huntsman Cancer Institute, University of Utah | Salt Lake City | Utah | 84112 | — |
| University of Virginia Health System | Charlottesville | Virginia | 22908 | — |
| Virginia Oncology Associates | Norfolk | Virginia | 23502 | — |
| Virginia Commonwealth University | Richmond | Virginia | 23219 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05459571, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 1, 2026 · Synced May 7, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05459571 live on ClinicalTrials.gov.